Sanofi-a Ventis Deutschland Gmbh

Aventis Pharma S.a.

Rhone-poulenc Rorer S.a.

Aventis Pharmaceuticals Inc.

Phone-poulenc Rorer Sa.

Bernard Baudoin

Alain Commercon

Frank Halley

Christopher Burns

Hans Matter

Michel Tabart

David William Will

Patrick Mailliet

Fabrice Viviani

Fabienne Thompson

Francois Clerc

Thomas Rooney

Karl Schönafinger

Catherine Souaille

Franck Halley

Gilles Tiraboschi

Marie-Pierre Cherrier

Laurence Gauzy-Lazo

Thorsten Naumann

Swen Hölder

Günther Müller

Dominique Le Suisse

Teresa Damiano

Michael L Edwards

Herve Bouchard

Hervé Bouchard

Tahir Nadeem Majid

Jean-Dominique Guitton

Stephanie Deprets

Paul Joseph Cox

David John Aldous

Iain M McLay

Anke Steinmetz

Brian L Pedgrift

Shelley Amendola

Ingrid Sassoon

Christopher D Edlin

Alain Le Brun

Cécile Combeau

Alain Lebrun

The present invention relates to novel pyridazinone derivatives of the general formula (I) wherein 

Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them

Substituted tetrahydro-1H-pyrazolo[3,4-c]pyridines, compositions comprising them and use. The present invention relates in particular to novel substituted tetrahydro-1H-pyrazolo[3,4-c]pyridines having therapeutic activity, which can be used in particular in oncology. 

[object Object]

The present invention relates to novel pyridazinone derivatives of the general formula (I)  

Compounds of the formula and N-oxides, prodrugs, acid bioisosteres, pharmaceutically acceptable salts or solvates of such compounds, or N-oxides, prodrugs, or acid bioisosteres of such salts or solvates, to compositions comprising such compounds, and methods of treatment comprising administering, to a patient in need thereof, such compounds and compositions.

Pyrrolopyrimidines

Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use

Novel farnesyl transferase inhibitors of general formula (I), ##STR1## the preparation thereof and pharmaceutical compositions containing said inhibitors, are disclosed. In general formula (I), R.sub.1 is Y--S--A.sub.1 (where Y is a hydrogen atom, an amino acid residue, a fatty acid residue, an alkyl or alkoxycarbonyl radical or a radical R.sub.4 --S-- where R.sub.4 is a C.sub.1-4 alkyl radical optionally substituted by a phenyl radical or a radical of general formula (II) ##STR2## wherein A.sub.1, X, X.sub.1, Y.sub.1, R'.sub.1, R.sub.2, R'.sub.2 and R are defined as below, and A.sub.1 is a C.sub.1-4 alkylene radical optionally alpha-substituted in the &gt;C(X.sub.1)(Y.sub.1) grouping by an amino or alkylamino, dialkylamino, alkanoylamino or alkoxycarbonylamino radical); X.sub.1 and Y.sub.1 are each a hydrogen atom or, taken together with the carbon atom to which they are attached, form a &gt;C.dbd.O grouping; R'.sub.1 is hydrogen or a C.sub.1-6 alkyl radical; X is an oxygen or sulphur atom; R.sub.2 is a C.sub.1-6 alkyl, alkenyl or alkynyl radical optionally substituted by hydroxyl, alkoxy, mercapto, alkylthio, alkylsulphinyl or alkylsulphonyl, with the proviso that when R.sub.2 is an alkyl radical substituted by a hydroxy radical, R.sub.2 can form a lactone with the .alpha.-carboxy radical; and R'.sub.2 is hydrogen or a C.sub.1-6 alkyl radical; and R is a hydrogen atom or an optionally substituted alkyl radical or an optionally substituted pheny radical, with the proviso that radical (a) ##STR3## is in the 3 or 4 position of the naphthyl ring. The novel products have anticancer properties.

Farnesyl transferase inhibitors, preparation thereof and pharmaceuticals

Farnesyl transferase inhibitors, their preparation and the

Farnesyl transferase inhibitors, preparation thereof and pharmaceutical

Growing community of inventors

Chaville, France

Bernard Baudoin